There is literature relating immunosuppressive drugs used for autoimmune diseases to the risk of cancer

Clinical studies have raised some doubts about cladribine being responsible for an increased risk of melanoma in multiple sclerosis patients

Our study demonstrates that at either low or high cladribine concentrations, there is no proliferation or differentiation of melanocytes

These results could affect future clinical practice for neurologists using cladribine for their MS patients and could influence monitoring

Data from registries are mandatory to confirm our in vitro study